Table 1.
First author/year | Region | Group | Patients /eyes (n) |
GA (weeks) (mean±SD) |
BW (g) (mean±SD) | Follow-up (months) |
Type of anti-VEGF |
Anti-VEGF dose (mg) | NOS score |
Harder 201318 | Germany | Anti-VEGF laser | 12/23 13/26 |
25.20±1.60 25.30±1.80 |
622.00±153.00 717.00±197.00 |
12 | Bevacizumab | 0.375 or 0.625 | 7 |
Hwang 201519 | American | Anti-VEGF laser | 11/22 17/32 |
NA | 668.10±127.30 701.40±118.80 |
21.7 32.5 |
Bevacizumab | 0.625 | 8 |
Kabatas11 2017* | Turkey | Anti-VEGF laser | 12/24 36/72 |
26.10±2.27 27.70±2.70 |
841.00±235.00 1112.00±362.00 |
18 | Bevacizumab | 0.625 | 8 |
Kabatas11 2017* | Turkey | Anti-VEGF laser | 6/12 36/72 |
26.00±1.26 27.70±2.70 |
840.00±177.00 1112.00±362.00 |
18 | Ranibizumab | 0.25 | 8 |
Kuo 201520 | Taiwan | Anti-VEGF laser | 15/15 14/14 |
27.33±2.94 27.43±2.93 |
1079.67±357.48 1006.79±327.65 |
3 years of age | Bevacizumab | 0.5 | 7 |
Kang 201921 | Korea | Anti-VEGF laser | 12/22 15/30 |
27.40±2.00 34.00±2.90 |
983.20±265.60 961.00±286.50 |
4 years of age | Bevacizumab ranibizumab | 0.625 0.2 |
7 |
Isaac 201522 | Canada | Anti-VEGF laser | 13/23 12/22 |
25.20±1.40 25.00±1.10 |
722.00±131.00 674.00±175.00 |
16.00±6.00 6.00±3.00 |
Bevacizumab | 0.625 | 8 |
Vujanović 201723 | Serbia | Anti-VEGF laser | 21/42 45/90 |
29.00±4.00 30.00±4.00 |
1175.00±425.00 1200.00±500.00 |
9 | Bevacizumab | 0.625 | 8 |
Gunay 201624* | Turkey | Anti-VEGF laser | 55/107 57/113 |
27.31±2.18 28.23±2.50 |
1005.29±411.19 1119.47±336.96 |
19.40±6.43 20.68±6.89 |
Bevacizumab | 0.625 | 8 |
Gunay 201624* | Turkey | Anti-VEGF laser | 22/44 57/113 |
27.95±2.90 28.23±2.50 |
1195.90±466.98 1119.47±336.96 |
18.96±4.79 20.68±6.89 |
Ranibizumab | 0.25 | 8 |
Chen 201925 | Taiwan | Anti-VEGF laser | 13/25 12/22 |
26.46±1.51 25.50±1.24 |
862.54±197.65 815.83±151.07 |
NA | Bevacizumab | 0.625 | 7 |
Lee 201826 | Taiwan | Anti-VEGF laser | 17/33 13/24 |
26.60±1.60 26.60±2.50 |
874.10±228.70 803.10±144.90 |
>48 | Bevacizumab | 0.625 | 6 |
Roohipoor 201827 | Iran | Anti-VEGF laser | NA/397 NA/190 |
27.8 | 1146 | >12 | Bevacizumab | 0.625 | 8 |
Geloneck 201416 | American | Anti-VEGF laser | 56/110 53/101 |
24.3 | 625 | 2.5 years of age | Bevacizumab | 0.625 | 8 |
O‘Keeffe 201617 | lrish | Anti-VEGF laser | 15/15 15/15 |
25±1.25 | 780±135 | 60 | Bevacizumab | 1.25 | 6 |
*There are two types of antivascular endothelial growth factor (VEGF) drugs included in the literature, so the details are listed separately.
BW, birth weight; GA, gestational age; NA, not applicable; NOS, Newcastle-Ottawa Scale; RCT, randomised controlled trial.